中药治疗非酒精性脂肪性肝纤维化的研究现状

非酒精性脂肪性肝纤维化是非酒精性脂肪性肝炎（NASH）进展为终末期肝病的关键病理阶段,其有效治疗亟待解决。中药具有多组分及多途径、多靶点作用的特点,对非酒精性脂肪性肝纤维化具有综合治疗的优势,可通过调节肝脏脂质代谢、抑制氧化应激反应及肝细胞凋亡、调节炎症、纤维化相关基因的表达等阻止肝脂肪变、炎症及纤维化的发生与进展。...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 29; no. 4; pp. 249 - 252
Main Author 南月敏 李文聪
Format Journal Article
LanguageChinese
Published 河北医科大学第三医院中西医结合肝病科,石家庄,050051 2013
Subjects
中草药
肝硬化
脂肪肝
脂肪肝
肝硬化
中草药
Online AccessGet full text
ISSN1001-5256

Cover

More Information
Summary:非酒精性脂肪性肝纤维化是非酒精性脂肪性肝炎（NASH）进展为终末期肝病的关键病理阶段,其有效治疗亟待解决。中药具有多组分及多途径、多靶点作用的特点,对非酒精性脂肪性肝纤维化具有综合治疗的优势,可通过调节肝脏脂质代谢、抑制氧化应激反应及肝细胞凋亡、调节炎症、纤维化相关基因的表达等阻止肝脂肪变、炎症及纤维化的发生与进展。
Bibliography:fatty liver ; liver cirrhosis ; drugs, Chinese herbal
The incidence of non - alcoholic fatty liver disease （NAFLD） continues to rise globally. Later stages of NAFLD are characterized by severe structural and functional perturbations in the liver, with the progressive clinical manifestations being fibrosis and cirrhosis, leading to end - stage liver disease. Thus, the pathogenic process of hepatic fibrosis has been a principal target of efforts to develop therapeutic inter- ventions capable of suppressing NAFLD progression, with tile aim of protecting liver function and ultimately promoting patient quality of life and survival. Extensive research has uncovered several of the molecular factors and signaling pathways leading to the excessive synthesis and deposition of extracellular matrix （ECM） or collagen, including those of inflammation, oxidative stress and apoptosis. In this review, we dis- cuss the potential of traditional Chinese medicine （TCM） herbs for inhibiting or resolving fibrosis by interacting with
ISSN:1001-5256